KEGG   DRUG: ElotuzumabHelp
Entry
D09337                      Drug                                   

Name
Elotuzumab (USAN);
Elotuzumab (genetical recombination) (JAN);
Empliciti (TN)
Product
Formula
C6476H9982N1714O2016S42
Exact mass
145361.9532
Mol weight
145451.5545
Remark
Therapeutic category: 4291
ATC code: L01XC23
Product: D09337<JP/US>
Efficacy
Antineoplastic, Anti-SLAMF7 antibody
  Disease
Multiple myeloma [DS:H00010]
Comment
Monoclonal antibody
Target
SLAMF7 (CD319) [HSA:57823] [KO:K06733]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC23 Elotuzumab
      D09337  Elotuzumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Elotuzumab
    D09337  Elotuzumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09337  Elotuzumab (USAN); Elotuzumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   CD2 family
    SLAMF7 (CD319)
     D09337  Elotuzumab (USAN) <JP/US>
Antineoplastics [br08340.html]
 D09337
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D09337
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09337
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09337
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09337
BRITE hierarchy
Other DBs
CAS: 915296-00-3
PubChem: 96026017
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system